Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CALLED @ .006 !! GO ME...lol
READ HERE !!!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46768746
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46763981
and more alerts..a shame didnt post on this particular one.
ash, who's running this co? Who's making the filings?
cw
This is a thin stock. MMs went out of shares on thursday. The volume was 2.5 million shares. 1.2 million shares were short!
On friday nearly 30 % of the volume were short again!
In my opinion they had to drive the pps down to get shares.
The pullback was on low volume, so this might be another sign for this.
ABPH european approval?! http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=47389&tid=126&mid=126&tof=1&frt=1
what an amazing tech, and if they announce European approval,1$,IMO
Why did this go down all day on friday after hitting its HOD at the thursday close ?
It looked to have some momo .I will be watching this one monday .
Huge short volume in the last two days:
http://regsho.finra.org/FORFshvol20100218.txt
Date|Symbol|ShortVolume|TotalVolume|Market
20100218|ABPH|1168826|2537619|O
http://regsho.finra.org/FORFshvol20100219.txt
Date|Symbol|ShortVolume|TotalVolume|Market
20100219|ABPH|188296|648921|O
don't give them any shares!
They had to pull it down to cover.
Huge short volume yesterday, MMs had no shares!
http://regsho.finra.org/FORFshvol20100218.txt
Date|Symbol|ShortVolume|TotalVolume|Market
20100218|ABPH|1168826|2537619|O
Down on low volume. Thin float easy to shake. A lot strong hands in this one
OMG Tried to buy this at close at .02!! SOOOO happy my trade was too late. Phew!! What a close one. woulda lost 50% already??? Scam...
Nothing official yet, that´s right. But there could be something true in these rumors. There was a presentation of study results in July last year. Those results of abph´s technology are looking good.
So in my opinion they continued working on the BioScanIR. Maybe there was a potential investor at a presentation that wants to bring this stuff to market now.
Link to the presentation:You can find it, if You type in 1801 at "Poster Number" on this page: http://www.aad.org/forms/ePosterPresentations/Default.aspx
The Presentation-Link:
http://www.aad.org/meetings/summer/abstracts/_doc/Melanoma%20and%20Pigmented%20Lesions.pdf
The study was sponsored by ABPH! (see at the end)
Melanoma and Pigmented Lesions
P1801
Dynamic infrared imaging (DIRI®) of pigmented lesions of the skin: A pilot study of a thermal and vascular imaging modality to distinguish malignant from benign lesions
Caroline C. Kim, MD, Pigmented Lesion Clinic and Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Erika Summers, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; John Mullen, MD, Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Maria Laura Gomez, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dynamic Infrared Imaging (DIRI) is a noninvasive imaging technique that passively records natural Infrared Radiation (IR) emitted from living tissues that has been shown to be able to detect minute temperature changes (0.006 degrees Celsius) and vasomotor changes to a depth of ~ 200 micrometers. We hypothesized that DIRI could detect such tissue surface changes induced by a cutaneous malignancy as compared to the surrounding normal skin. A pilot study was conducted examining twenty patients from our Cutaneous Oncology and Pigmented Lesion Clinics with suspicious skin lesions that warranted biopsy to assess the utility of DIRI in skin lesions. Suspicious skin lesions were scanned with DIRI then biopsied, and DIRI results were compared to the histologic diagnoses. The investigators were blinded throughout the study and all scans were analyzed by Advanced BioPhotonics, Inc. A total of 24 skin lesions were analyzed including 4 melanomas (1 invasive, 1 melanoma in-situ, 2 metastatic), 1 squamous cell in-situ (SCCIS), and 19 benign skin lesions. DIRI correctly identified 4 out of 4 melanomas as malignant, and 15 out of 19 benign lesions as benign, while there were 4 false positive results (benign and atypical nevi) and one false negative result (SCCIS). For all cancers, it had a diagnostic sensitivity of 80 % (95% confidence interval [CI]: 28-100%), and a specificity of 78.9% (95% CI: 54-94%). For melanoma detection, however, it had a sensitivity of 100% (95% CI: 40-100%) and specificity of 80% (95% CI: 56-94%). It is notable that DIRI correctly identified the melanoma in-situ as having an altered thermal and tissue perfusion pattern rendering the malignant interpretation, perhaps suggesting that underlying vasomotor changes are already evident at this early stage of disease. In contrast, other skin tumors such as SCCIS may not have such changes. Scanning technique is being reevaluated to assess the false positive scans, given the extreme sensitivity of the instrument to temperature shifts. In summary, this is the first study using a thermal and vascular imaging modality in the investigation of cutaneous melanoma. The results, though preliminary and from a small sample, warrant further investigation with this novel imaging technique in the screening of pigmented skin lesions for cutaneous melanoma.
Commercial Support: 40% of research costs sponsored by Advanced BioPhotonics, Inc.
are you guys investing in a ghost? no web site, no filings in 2 years,no news
most of info we have is dated 2006, the following one is dated feb 01, 2008:
Advanced BioPhotonics received a Phase I Small Business Innovation Research (SBIR) grant to develop an integrated portable infrared camera system that could meet MDA’s booster-typing needs as well as advance the next innovations in infrared medical imaging.
http://www.defensetechbriefs.com/component/content/article/4768
Could it be?Could this be another vkng in the making?Sure has a comparable float and same explosive movement.I chickened out on vkng @ .03 because it was up 1000% in 1 day so why should I chicken out on this bad boy up 200% in half a day?I am in my friends because I sense this ones going to the moon!
Nice call ash111! I just smelled this nice move ....
Would like to see a news release on Monday.
cw
another research paper, thou dated jun'06 and is being in use even now...
http://jtcs.ctsnetjournals.org/cgi/reprint/131/6/1344.pdf?ref=ARKADASBUL.NET
United States Diagnostic Imaging Investment Opportunities,
Analysis and Forecasts to 2012
see the report below, ABPH mentioned in this. i dont know the date of this report.
http://www.researchandmarkets.com/reports/603410/united_states_diagnostic_imaging_investment.pdf
Huge find, should go BIG TIME.
Fantastic day - big multiday run has stared.
Well I'll never lead ya wrong baby! Haha see ya tomorrow.
Salute soldier
)
easy double tomorrow !!!
after that ??$??
My last post then im out of them today. Im in the military I make crap i have some money from my deployment this is all i have and I wwanna no if this is just a pump maybe some one will be honest enough to say. I dont know what to think i jumped in made some money and for people to say this is going to run it raises questions on how and why. So stand down and just answer the quesitons at hand. I cant see all the charts from my job in the military wont allow so I go in blind some times and hope for the best. Som times unfortunatly I have to go off other people.
Awesome - Can't wait till tomorrow. GLTA, even Squad. Lol
Squadron, everytime a stock starts doing good, here u come. Please stop. Good energy on this board. You seem to like to cause doubt with the investors who may not know better than to listen to u. The first few times I saw u do this I thought u were a paid basher, but this is too quick. Do u just get a kick out of doing this type of stuff? Seriously.
HOD close, very nice! See you tomorrow...
so the run is REAL....!!! not just a PUMP. Looks like pre-news run.
Closed HOD = Very Bullishhhhhhhh
I dont see it though im on a secured network in the military and jumped in at .014 so ive made profit just hesitant about tomorrow. Any still in for tomorrow?
for sure? This seems like this is it here.
Just hit .0199! Closing on high of day - AWESOME!
monster in the making.
ABPH - (1)@.0199 (1)@.02 (1)@.04 (2)@.07 then $1!
Look @ the 3yr chart = .045 first resist.
http://stockcharts.com/h-sc/ui?s=ABPH&p=D&yr=3&mn=0&dy=0&id=0
Big gappa tomorrow, no shares left.
.016 , you already up15%
Agree, tomorrow will be huge!
Agree, tomorrow will be huge!
ABPH, buy this now before the close, or watch it go BIGGLY tomorrow imo
LOL, I think u will do VERY VERY well.
Well im in @.014 thoughts of any more of a run or did I just get screwed.lol
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
840
|
Created
|
03/09/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/h?s=ABPH.PK
BioScanIR® The most advanced infrared sensors used in Space are now part of the most advanced biomedical infrared imaging system on the planet - the BioScanIR® System:
Detects dynamic changes in blood perfusion in tissue and organs by sensing minute changes in thermal photon flux
Completely non-invasive—no contrast agents, no ionizing radiation used
Fast results—scans in 20 seconds and data reports available in minutes
Low cost—up to 80% less than other functional imaging modalities FDA-Cleared, UL-Certified and CE-Marked
The BioScanIR System is an infrared-based functional imaging system that detects minute changes in blood perfusion through the capture of passively-emitted infrared radiation that is produced by tissue. Through the analysis of this captured radiation, the system can help physicians and researchers differentiate between normal and abnormal tissue. In this fashion, the BioScanIR System can detect diseases and conditions that affect the perfusion or reperfusion of blood in tissue and organs.
The BioScanIR System is totally non-invasive, and does not contact the patient in any way. It uses no radiation, and requires no contrast agent. It can be used by non-imaging specialists, and can be used in a non-sterile, office environment. The BioScanIR System has multiple clinical applications including:
Monitoring response to cancer drug therapy.
Monitoring intervention in diabetic driven peripheral vascular disease.
Identifying perforator vessels during pre-surgical planning, and assessing post-operative perfusion of pedicle flaps following reconstructive surgery (i.e. of the breast).
Mapping of functional cortex in patients undergoing tumor surgery.
Determining cardiac bypass graft patency and perfusion of the myocardium in cardiac surgery.
The BioScanIR System can be used adjunctively with more expensive modalities such as CT, MRI, functional MRI and PET imaging.
To learn more about specific clinical use, visit our Applications Section
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
by Ronald C. Trahan
A PREVIEW OF EARLY-STAGE
MEDICAL TECHNOLOGY COMPANIES
The latest Filings and News:
December 17th 2007..... Big News.... Please Read
http://biz.yahoo.com/bw/071217/20071217006052.html?.v=1
MISC NEWS:
Frost & Sullivan's 2005 Medical Imaging in Cancer & Vascular Disease Diagnostics Product Leadership of the Year Award
http://medgadget.com/archives/2005/03/the_bioscanir_s.html
OmniCorder Technologies Installs BioScanIR System at Leading German Cancer Center
http://findarticles.com/p/articles/mi_m0EIN/is_2004_Feb_18/ai_113374281
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
http://www.medtechinsight.com/advertorials/starwars.pdf
12-20-07 The following info was furnished by Mgland. He spoke directly to the TA
OS. The Transparency we embrace. Company has been very prudent here with the share structure but does have to pay the bill with things coming to fruition.
52 MILLION @ .0011 GIVES A MKT CAP OF $57,200.
OS by date (2007)
On 5/30 it was 38 million
on 6/22 39 million
7/10 40 million
9/25 unchanged
11/23 unchanged
11/30 42 million
12/19 52 million
(2009)
2/26 58 million (confirmed by FatFinger6)
It ran from pennies to $9 in 2004
Advanced BioPhotonics, Inc., a development stage company, engages in the development and commercialization of digital imaging technology for the diagnosis and management of various diseases, including cancer and vascular diseases in the United States. Its principal product includes BioScanIR system, which detects diseases that affect the perfusion or reperfusion of blood in tissues and organs. The BioScanIR system assists physicians and researchers in differentiating between normal and abnormal tissues by detecting small changes in perfusion. Advanced BioPhotonics, formerly known as OmniCorder Technologies, Inc., was founded in 1997 and changed its name to Advanced BioPhotonics, Inc. in 2005. The company is headquartered in Bohemia, New York.
Planned Clinical Trials in 2007.
· Pigmented Lesions of the Skin assessment (Melanoma). Melanoma detection and assessment represents a large clinical problem and a disease state where the BioScanIR® system may readily measure and assess the primary photonic emissions of skin tumors. In July 2007, we began a pilot research trial at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School. The first results for this trial are anticipated to be available in late November 2007. ·
Adjunctive screening and detection of breast cancer. The use of the BioScanIR® system as an adjunctive technique in breast cancer detection in certain age categories still holds great promise. This application may be particularly useful in younger women (under 50 years of age) with dense breasts who are at increased risk for breast cancer. We will continue to support the current work being done at the State University of New York Stony Brook in this area. First results should be available in late 2007.
We intend to concentrate our efforts and pursue clinical trials in the above noted applications provided that we have sufficient funds to do so. Previously, we had reported that we had also intended to organize a clinical trial to test the assessment of peripheral perfusion. The assessment of peripheral perfusion after tourniquet stress is a non invasive method of measuring peripheral outflow as a measure of systemic vascular disease. The current methods employ ultrasound techniques over which we may have significant benefits. After further investigation, we have decided to focus our limited assets on pigmented lesions of the skin assessment (Melanoma) and adjunctive screening and detection of breast cancer. As of November 1, 2007, we had two fully functional prototype or commercial units installed in various U.S. medical institutions for testing and evaluation.
Gallery View 4: (Full Sto, MACD, Aroon8)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |